In Brief: Perclose
This article was originally published in The Gray Sheet
Perclose: Submits premarket approval application supplement to FDA for its Prostar Plus and Prostar XL next-generation surgical closure systems for arterial access sites. The submissions for the 8 Fr and 10 Fr Prostar Plus and 8 Fr Prostar XL follow the firm's April 30 PMA approval for the Prostar first-generation system ("The Gray Sheet" May 5, I&W-1). The supplement is supported by data from the 515-patient, seven-site Sutures to Ambulate and Discharge (STAND) II trial. Preliminary results disclosed in May indicated the Prostar Plus reduced the average length of patient hospitalization by 14% compared to conventional treatment ("The Gray Sheet" May 26, In Brief)...
You may also be interested in...
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.
UK-based charity International Health Partners has launched a fresh appeal to double the value funds being raised to send essential medicines to expectant mothers and children at risk of death in areas of extreme deprivation.
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.